Dina Hany

ORCID: 0000-0003-1872-8641
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Heat shock proteins research
  • Genetics, Aging, and Longevity in Model Organisms
  • Viral Infectious Diseases and Gene Expression in Insects
  • Spaceflight effects on biology
  • Histone Deacetylase Inhibitors Research
  • Computational Drug Discovery Methods
  • Estrogen and related hormone effects
  • Protein Structure and Dynamics
  • CRISPR and Genetic Engineering
  • PI3K/AKT/mTOR signaling in cancer
  • Advanced Breast Cancer Therapies
  • Advanced biosensing and bioanalysis techniques
  • Genetic factors in colorectal cancer
  • Cancer Genomics and Diagnostics
  • Click Chemistry and Applications
  • Exercise and Physiological Responses
  • Melanoma and MAPK Pathways
  • Colorectal Cancer Treatments and Studies
  • Cancer therapeutics and mechanisms
  • Cancer-related Molecular Pathways

University of Geneva
2022-2023

Pharos University in Alexandria
2022-2023

HES-SO University of Applied Sciences and Arts Western Switzerland
2023

Abstract The cytosolic molecular chaperone Hsp90 is essential for eukaryotic life. Although reduced levels correlate with aging, it was unknown whether cells and organisms can tune the basal to alleviate physiologically accumulated stress. We have investigated how mice adapt deletion of three out four alleles two genes encoding Hsp90, one Hsp90β allele being only remaining one. While vast majority such mouse embryos die during gestation, survivors apparently manage increase their protein at...

10.1038/s41467-022-33916-3 article EN cc-by Nature Communications 2022-10-21

We propose a new approach for designing personalized treatment colorectal cancer (CRC) patients, by combining ex vivo organoid efficacy testing with mathematical modeling of the results.The validated phenotypic called Therapeutically Guided Multidrug Optimization (TGMO) was used to identify four low-dose synergistic optimized drug combinations (ODC) in 3D human CRC models cells that are either sensitive or resistant first-line chemotherapy (FOLFOXIRI). Our findings were obtained using second...

10.1186/s13046-023-02650-z article EN cc-by Journal of Experimental & Clinical Cancer Research 2023-04-03

In breast cancer, resistance to endocrine therapies that target estrogen receptor α (ERα), such as tamoxifen and fulvestrant, remains a major clinical problem. Whether how ERα + cancers switch from being estrogen-dependent estrogen-independent unclear. With genome-wide CRISPR-Cas9 knockout screen, we identified previously unknown biomarkers potential therapeutic targets of resistance. We demonstrate high levels PAICS, an enzyme involved in the de novo biosynthesis purines, can shift balance...

10.1126/sciadv.add3685 article EN cc-by-nc Science Advances 2023-05-12

Breast cancer is the number one cause of cancer-related mortality in women worldwide. Most breast tumors depend on expression estrogen receptor α (ERα) for their growth. For this reason, targeting ERα with antagonists such as tamoxifen therapy choice most patients. Although initially responsive to tamoxifen, about 40% patients will develop resistance and ultimately a recurrence disease. Thus, finding new biomarkers therapeutic approaches treatment-resistant high significance. SPRED2, an...

10.3390/cancers14040954 article EN Cancers 2022-02-14

Cells are exposed to a wide variety of internal and external stresses. Although many studies have focused on cellular responses acute severe stresses, little is known about how systems adapt sublethal chronic Using mammalian cells in culture, we discovered that they mild stresses up two weeks, notably proteotoxic such as heat, by increasing their size translation, thereby scaling the amount total protein. These adaptations render them more resilient persistent subsequent We demonstrate Hsf1,...

10.7554/elife.88658 article EN cc-by eLife 2023-06-02

Abstract Breast cancer is a persistent threat to women worldwide. A large proportion of breast cancers are dependent on the estrogen receptor α (ERα) for tumor progression. Therefore, targeting ERα with antagonists, such as tamoxifen, or deprivation by aromatase inhibitors remain standard therapies + cancer. The clinical benefits monotherapy often counterbalanced off-target toxicity and development resistance. Combinations more than two drugs might be great therapeutic value prevent...

10.1007/s00018-023-04730-x article EN cc-by Cellular and Molecular Life Sciences 2023-03-01

Cells are exposed to a wide variety of internal and external stresses. Although many studies have focused on cellular responses acute severe stresses, little is known about how systems adapt sublethal chronic Using mammalian cells in culture, we discovered that they mild stresses up two weeks, notably proteotoxic such as heat, by increasing their size translation, thereby scaling the amount total protein. These adaptations render them more resilient persistent subsequent We demonstrate Hsf1,...

10.7554/elife.88658.3 article EN cc-by eLife 2023-12-07

Abstract In breast cancer, resistance to endocrine therapies that target estrogen receptor α (ERα), such as tamoxifen and fulvestrant, remains a major clinical problem. Whether how ERα+ cancers switch from being estrogen-dependent -independent unclear. With genome-wide CRISPR/Cas9 knockout screen, we identified new biomarkers potential therapeutic targets of resistance. We demonstrate high levels PAICS, an enzyme involved in the de novo biosynthesis purines, can shift balance ERα activity be...

10.1101/2022.06.03.494664 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2022-06-03

Abstract Cells are exposed to a wide variety of internal and external stresses. Whereas many studies have focused on cellular responses acute severe stresses, little is known about how systems adapt sublethal chronic Using mammalian cells in culture, we discovered that they mild stresses up two weeks, notably proteotoxic such as heat, by increasing their size translation, thereby scaling the amount total protein. These adaptations render them more resilient persistent subsequent We...

10.1101/2023.01.25.525547 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2023-01-25

Abstract The cytosolic molecular chaperone Hsp90 is essential for eukaryotic life 1, 2 . It involved in multiple branches of proteostasis 2, 3 , and as a capacitor morphological evolution 4 Although reduced levels cause phenotypic variations 5, 6 correlate with aging 7 whether cells organisms can tune the basal protein to alleviate physiologically accumulated stress unknown. To begin explore this question, we investigated how mice adapt deletion three out four alleles encoding Hsp90, one...

10.1101/2022.02.11.480086 preprint EN cc-by-nc bioRxiv (Cold Spring Harbor Laboratory) 2022-02-11

Cells are exposed to a wide variety of internal and external stresses. Whereas many studies have focused on cellular responses acute severe stresses, little is known about how systems adapt sublethal chronic Using mammalian cells in culture, we discovered that they mild notably proteotoxic stresses such as heat, by increasing their size translation, thereby scaling the amount total protein. These adaptations render them more resilient persistent subsequent We demonstrate Hsf1, well for its...

10.7554/elife.88658.1 preprint EN 2023-06-02

Cells are exposed to a wide variety of internal and external stresses. Whereas many studies have focused on cellular responses acute severe stresses, little is known about how systems adapt sublethal chronic Using mammalian cells in culture, we discovered that they mild stresses up two weeks, notably proteotoxic such as heat, by increasing their size translation, thereby scaling the amount total protein. These adaptations render them more resilient persistent subsequent We demonstrate Hsf1,...

10.7554/elife.88658.2 preprint EN 2023-11-13

Abstract Breast cancer is a persistent threat to women worldwide. A large proportion of breast cancers are dependent on estrogen receptor α (ERα) for tumor progression. Therefore, targeting ERα with antagonists, such as tamoxifen, remains standard therapy ERα+ cancer. The clinical benefits monotherapy often counterbalanced by off-target toxicity and development resistance. Combinations more than two drugs might be great therapeutic value prevent resistance, reduce doses, hence, toxicity. We...

10.1101/2022.08.30.505871 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2022-09-03
Coming Soon ...